2006 Heart-Brain summit proceedings
Heart-brain medicine:
Where we go from here and why
ARTICLE INTRODUCTION
This past June, the Earl and Doris Bakken Heart-Brain Institute (BHBI) held the first annual Heart-Brain Summit at the Cleveland Clinic. The BHBI’s goal is to investigate physiological and molecular relationships between the heart and the brain and to translate these findings into strategies to improve patient outcomes.
The need for this type of innovative approach for the development of novel therapies has never been greater. Modern medicine, through the development of early diagnostic imaging and endovascular approaches, has significantly reduced the morbidity and mortality of previously devastating acute conditions such as acute myocardial infarction and subarachnoid hemorrhage. In the case of acute myocardial infarction, 30-day mortality rates have declined from nearly 20% two decades ago to less than 5% in recent clinical trials using primary percutaneous intervention. This amazing achievement has unfortunately fostered a population of patients with chronic heart failure, which has a prevalence of greater than 5 million in the United States and affects more than 10% of the US population older than 65 years. While significant efforts have been put forth to improve outcomes in patients with chronic heart failure, mortality rates in clinical trials have not decreased significantly over the same span of time.
CITATIONS
- MS, Topol E.
The challenge for stem cell therapy. In: Penn MS, ed. Stem Cells and Myocardial Regeneration. Totowa, NJ: Humana Press; 2007:1–8. - Bardy GH, Lee KL, Mark DB, et al.
2005. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225–237.
http://www.ncbi.nlm.nih.gov/pubmed/15659722 - Young JB, Abraham WT, Smith AL, et al.
Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003; 289:2685–2694.
http://www.ncbi.nlm.nih.gov/pubmed/12771115 - Beqqali A, Kloots J, Ward-van Oostwaard D, Mummery C, Passier R.
Genome-wide transcriptional profiling of human embryonic stem cells differentiating to cardiomyocytes. Stem Cells 2006; 24:1956–1967.
http://www.ncbi.nlm.nih.gov/pubmed/16675594 - Leung H, Kwan P, Elger CE.
Finding the missing link between ictal bradyarrhythmia, ictal asystole, and sudden unexpected death in epilepsy. Epilepsy Behav 2006; 9:19–30.
http://www.ncbi.nlm.nih.gov/pubmed/16809068 - Casserly I, Topol E.
Convergence of atherosclerosis and Alzheimer’s disease: inflammation, cholesterol, and misfolded proteins. Lancet 2004; 363:1139–1146.
http://www.ncbi.nlm.nih.gov/pubmed/15064035 - Gidday JM.
Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci 2006; 7:437–448.
http://www.ncbi.nlm.nih.gov/pubmed/16715053 - Kloner RA, Rezkalla SH.
Preconditioning, postconditioning and their application to clinical cardiology. Cardiovasc Res 2006; 70:297–307.
http://www.ncbi.nlm.nih.gov/pubmed/16516180 - Southerland EM, Milhorn DM, Foreman RD, et al.
Preemptive, but not reactive, spinal cord stimulation mitigates transient ischemia-induced myocardial infarction via cardiac adrenergic neurons. Am J Physiol Heart Circ Physiol 2007; 292:H311–H317.
http://www.ncbi.nlm.nih.gov/pubmed/16920800 - Goldstein DS, Eldadah B, Holmes C, Pechnik S, Moak J, Sharabi Y.
Neurocirculatory abnormalities in chronic orthostatic intolerance. Circulation 2005; 111:839–845.http://www.ncbi.nlm.nih.gov/pubmed/15699262